Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

38.94USD
25 Apr 2018
Change (% chg)

$-1.31 (-3.25%)
Prev Close
$40.25
Open
$40.08
Day's High
$40.14
Day's Low
$38.45
Volume
1,860,873
Avg. Vol
1,742,700
52-wk High
$47.81
52-wk Low
$29.44

Select another date:

Wed, Apr 25 2018

BRIEF-Mylan Adds To Growing Women's Healthcare Portfolio With Launch Of Generic For Oral Contraceptive Yaz

* MYLAN ADDS TO GROWING WOMEN'S HEALTHCARE PORTFOLIO WITH LAUNCH OF GENERIC FOR ORAL CONTRACEPTIVE YAZ®

EpiPen shortages seen in Canada, UK but U.S. supply intact

NEW YORK Mylan N.V.'s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday.

EpiPen shortages seen in Canada, UK but U.S. supply intact

NEW YORK, April 13 Mylan N.V.'s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday.

Deals of the day-Mergers and acquisitions

April 13 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:

Mylan seeks deal for German Merck's consumer products unit: sources

FRANKFURT/NEW YORK Generic drug maker Mylan NV is in advanced discussions to acquire Merck KGaA's consumer health business after other bidders failed to meet the German company's price expectations, people familiar with the matter said.

UPDATE 2-Mylan seeks deal for German Merck's consumer products unit -sources

FRANKFURT/NEW YORK, April 13 Generic drug maker Mylan NV is in advanced discussions to acquire Merck KGaA's consumer health business after other bidders failed to meet the German company's price expectations, people familiar with the matter said.

Mylan seeks deal for German Merck’s consumer products unit -sources

FRANKFURT/NEW YORK, April 13 Generic drug maker Mylan is in advanced discussions to acquire Merck KGaA’s consumer health unit after other bidders failed to meet the German company’s price expectations, people familiar with the matter said.

BUZZ-India's Biocon rises; partner Mylan, FKB sign deal for drug in EU

** Biocon Ltd rises as much as 2.8 pct to 629.85 rupees, highest in over a month

BRIEF-Mylan Acquires Global Development & Marketing Rights For Meloxicam

* MYLAN - ACQUIRED GLOBAL DEVELOPMENT & MARKETING RIGHTS FROM PRAYOG LABS TO BRING TO MARKET FAST-ACTING MELOXICAM AS PROPOSED NON-NARCOTIC ANALGESIC

BRIEF-Mylan NV Says Reaffirming 2018 Guidance

* FY2018 EARNINGS PER SHARE VIEW $5.38, REVENUE VIEW $12.44 BILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

Select another date: